| Literature DB >> 23573133 |
Chyi Lo1, Wen-Chun Liao, Jen-Jiuan Liaw, Liang-Wen Hang, Jaung-Geng Lin.
Abstract
Study Objectives. To examine the stimulation effect of auricular magnetic press pellet therapy on older female adults with sleep disturbance as determined by polysomnography (PSG). Design. Randomized, single-blind, experimental-controlled, parallel-group. Setting. Community. Participants. Twenty-seven older female adults with sleep disturbance according to the Pittsburgh Sleep Quality Index (PSQI) >5 for at least 3 months were recruited. Participants were screened by both the Hospital Anxiety and Depression Scale (HADS) and the Mini-Mental State Examination (MMSE), as well as polysomnography prior to randomization. Interventions. All eligible participants were randomly allocated into the experimental or control group. Both groups were taped with magnetic press pellet on auricular points for 3 weeks. The experimental group was treated by applying pressure on the magnetic press pellets 3 times per day while no stimulation was applied on the control group. Measurements and Results. Both groups were measured by PSG and PSQI at the beginning of the study and 3 weeks after the study. Both groups showed improvements on PSQI scores compared to the baseline. One-way analysis of covariance adjusted for baseline scores showed that significant improvements of PSG-derived sleep parameters, such as sleep efficiency, were found in the experimental group. However, no significant differences between groups were observed in the proportion of sleep stages with the exception of Stage 2. Conclusions. Auricular therapy using magnetic pellets and stimulation by pressing was more effective in improving the sleep quality compared to auricular therapy without any stimulation.Entities:
Year: 2013 PMID: 23573133 PMCID: PMC3618916 DOI: 10.1155/2013/530438
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Flow of participants through the trial.
Figure 2The location of selected auricular acupoints—frontal surface.
Demographic data of participants in the experimental and control group.
| Variables | Experiment ( | Control ( |
|---|---|---|
| Mean ± SD | Mean ± SD | |
| Age, years | 57.0 ± 4.6 | 56.8 ± 4.9 |
| Insomnia duration, month | 92.4 ± 84.39 | 105.5 ± 102.83 |
| BMI#, % | 22.59 ± 2.74 | 22.56 ± 2.98 |
| MMSE# | 29.2 ± 0.9 | 28.9 ± 1.3 |
| HADS#_anxiety | 3.6 ± 3.3 | 3.4 ± 2.5 |
| HADS#_depression | 2.9 ± 2.7 | 2.9 ± 2.4 |
|
| ||
|
|
| |
|
| ||
| Retired | 4 (28.6%) | 5 (38.5%) |
| Education level | ||
| Middle school or below | 4 (28.6%) | 5 (38.5%) |
| High school | 6 (42.8%) | 6 (46.2%) |
| College or above | 4 (28.6%) | 2 (15.4%) |
| Marriage: married | 11 (78.6%) | 10 (76.9%) |
| Religion | ||
| None or other | 2 (14.2%) | 2 (15.4%) |
| Buddhist | 6 (42.9%) | 5 (38.5%) |
| Folk religion | 6 (42.9%) | 6 (46.2%) |
| Living status | ||
| With spouse | 4 (28.6%) | 1 (7.7%) |
| With children | 3 (21.4%) | 7 (53.8%) |
| With spouse and | 5 (35.7%) | 4 (30.8%) |
| Other | 2 (14.3%) | 1 (7.7%) |
| Other family members suffering from insomnia | 6 (42.9%) | 7 (53.8%) |
#BMI: body mass index; MMSE: Mini-Mental State Examination; HADS: Hospital Anxiety and Depression Scale.
Comparisons of seven components and global score of PSQI between the experimental group and the control group by analysis of covariance (ANCOVA).
| Items of PSQI | Pretest | Posttest | ANCOVA | |||
|---|---|---|---|---|---|---|
| Experiment | Control | Experiment | Control |
|
| |
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | |||
| C1. Sleep quality | 2.47 ± 0.52 | 2.46 ± 0.52 | 0.80 ± 0.56 | 1.31 ± 0.75 | 4.73 | 0.04* |
| C2. Sleep latency | 2.87 ± 0.52 | 2.69 ± 0.63 | 1.33 ± 0.82 | 1.77 ± 0.73 | 2.48 | 0.13 |
| C3. Sleep duration | 2.53 ± 0.64 | 2.54 ± 0.66 | 1.07 ± 0.70 | 1.92 ± 0.95 | 5.17 | 0.03* |
| C4. Sleep efficiency | 2.33 ± 0.82 | 2.62 ± 0.77 | 0.80 ± 1.15 | 1.85 ± 1.14 | 5.41 | 0.02* |
| C5. Sleep disturbances | 1.00 ± 0.38 | 1.08 ± 0.28 | 0.73 ± 0.46 | 1.15 ± 0.38 | 7.06 | 0.01* |
| C6. Sleeping medication | 1.07 ± 1.28 | 0.77 ± 1.24 | 0.00 ± 0.00 | 0.15 ± 0.38 | 0.84 | 0.37 |
| C7. Daytime dysfunction | 1.20 ± 1.08 | 1.54 ± 0.97 | 0.33 ± 0.62 | 1.08 ± 0.95 | 4.47 | 0.04* |
| PSQI global score | 13.40 ± 2.90 | 13.69 ± 1.97 | 5.07 ± 2.63 | 9.23 ± 3.63 | 9.10 | 0.00** |
*P < 0.05; **P < 0.01.
Comparisons of the sleep parameters detected by PSG between the experimental group and the control group by analysis of covariance (ANCOVA).
| Sleep parameters | Pretest | Posttest | ANCOVA | |||
|---|---|---|---|---|---|---|
| Experiment | Control | Experiment | Control |
|
| |
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | |||
| Sleep latency (to Stage 1) (min) | 17.57 ± 11.27 | 20.58 ± 13.13 | 12.04 ± 6.74 | 24.27 ± 15.48 | 6.78 | 0.02* |
| Total sleep time (min) | 356.29 ± 51.61 | 335.65 ± 54.97 | 362.14 ± 31.46 | 314.31 ± 66.96 | 5.87 | 0.02* |
| Sleep period time (min) | 423.75 ± 45.67 | 416.00 ± 49.21 | 409.18 ± 35.34 | 401.62 ± 41.89 | 0.18 | 0.67 |
| SE# (TST/TIB) (%) | 79.58 ± 7.54 | 76.99 ± 12.62 | 84.04 ± 4.62 | 72.15 ± 12.78 | 10.85 | 0.00** |
| Sleep stages (min in sleep period time) | ||||||
| Wake (WASO#) | 61.75 ± 38.72 | 80.35 ± 48.76 | 47.04 ± 24.07 | 87.31 ± 50.42 | 6.90 | 0.02* |
| Stage 1 | 54.82 ± 42.87 | 50.85 ± 29.74 | 42.93 ± 15.60 | 60.62 ± 50.58 | 2.22 | 0.15 |
| Stage 2 | 208.43 ± 56.22 | 187.23 ± 41.12 | 208.46 ± 47.28 | 158.15 ± 54.67 | 6.29 | 0.02* |
| Stage 3 | 10.21 ± 15.31 | 14.62 ± 20.65 | 11.64 ± 15.45 | 15.92 ± 21.01 | 0.17 | 0.69 |
| Stage 4 | 0.93 ± 3.06 | 4.08 ± 12.51 | 0.64 ± 1.99 | 2.81 ± 8.50 | 0.48 | 0.50 |
| REM | 87.61 ± 27.93 | 78.88 ± 23.55 | 98.46 ± 34.01 | 76.81 ± 26.24 | 2.08 | 0.16 |
| NREM | 274.39 ± 30.12 | 256.77 ± 42.75 | 263.68 ± 42.71 | 237.50 ± 52.26 | 0.56 | 0.46 |
| SWS | 11.14 ± 18.11 | 18.69 ± 31.40 | 12.29 ± 16.64 | 18.73 ± 27.83 | 0.02 | 0.89 |
| Sleep stages ( | ||||||
| Wake (WASO#) | 14.36 ± 8.03 | 19.17 ± 11.28 | 11.34 ± 5.36 | 21.96 ± 13.20 | 6.74 | 0.02* |
| Stage 1 | 13.03 ± 9.89 | 11.96 ± 6.34 | 10.43 ± 3.52 | 15.15 ± 13.16 | 1.98 | 0.17 |
| Stage 2 | 49.50 ± 13.27 | 45.80 ± 11.54 | 50.90 ± 10.27 | 39.18 ± 12.24 | 4.75 | 0.04* |
| Stage 3 | 2.35 ± 3.52 | 3.03 ± 4.39 | 2.86 ± 3.73 | 3.90 ± 5.00 | 0.03 | 0.87 |
| Stage 4 | 0.21 ± 0.72 | 0.79 ± 2.34 | 0.14 ± 0.45 | 0.68 ± 2.03 | 0.03 | 0.87 |
| REM | 21.21 ± 4.79 | 19.04 ± 5.48 | 24.31 ± 8.61 | 19.12 ± 6.35 | 2.73 | 0.11 |
| Arousal index | 14.57 ± 5.01 | 15.27 ± 2.65 | 12.99 ± 5.00 | 16.78 ± 3.97 | 4.81 | 0.04* |
#SE: sleep efficiency; WASO: wake after sleep onset.
*P < 0.05; **P < 0.01.
Figure 3The changes of sleep latency and sleep efficiency detected by PSG between the experimental group and the control group.